A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies

被引：0
|
作者：
Chia, S. K.
Chi, K. N.
Kollmannsberger, C.
Paton, K.
Bhagat, K.
D'Aloisio, S.
Das-Gupta, A.
Kletzl, H.
Zwanziger, E.
Gelmon, K.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC, Canada
[2] Vancouver Gen Hosp, Vancouver, BC, Canada
[3] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
    Chia, S.
    Chi, K.
    Kollmannsberger, C.
    Paton, K.
    Bhagat, K.
    D'Aloisi, S.
    Das-Gupta, A.
    Kletzl, H.
    Zwanziger, E.
    Gelmon, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 109 - 109
  • [2] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
    Agarwala, SS
    Bukowski, RM
    Kirkwood, J
    Weiss, P
    Olencki, T
    Grzegorewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
  • [3] PHASE I DOSE ESCALATION AND PHARMACOKINETIC (PK) STUDY OF IV AFLIBERCEPT (VEGF TRAP) PLUS WEEKLY GEMCITABINE AND DAILY ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS
    Sarantopoulos, J.
    Rosen, L.
    Chap, L.
    Mita, A.
    Papadopoulos, K.
    Mita, M.
    Wood, L.
    Nichols, S.
    Tolcher, A.
    Trembly, J.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 57 - 57
  • [4] A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors
    Macpherson, I.
    Stewart, K.
    Chick, J.
    Brock, K.
    Poondru, S.
    Gedrich, R.
    Stephens, A. W.
    Evans, T. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
    Spiridonidis, CH
    Laufman, LR
    Jones, J
    Rhodes, VA
    Wallace, K
    Nicol, S
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3866 - 3873
  • [6] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [7] A phase 1 dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients.
    Sweeney, C
    Porter, J
    Mann, L
    Yoder, C
    Fife, K
    Murry, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 144S - 144S
  • [8] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [9] A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies
    Bannerji, Rajat
    Saltzman, Marc
    Rosenberg, Mitchell A.
    Small, Karen
    Black, Stuart
    Kirschmeier, Paul
    Statkevich, Paul
    Abutarif, Malaz
    Parry, David
    Yao, Siu-Long
    Nernunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3372S - 3373S
  • [10] A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors
    Bryan Schneider
    Anna Fukunaga
    Daryl Murry
    Christy Yoder
    Karen Fife
    Anne Foster
    Leslie Rosenberg
    Stephanie Kelich
    Lang Li
    Christopher Sweeney
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 261 - 268
12345